Bolt BiotherapeuticsBOLT
BOLT
About: Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
Employees: 100
0
Funds holding %
of 6,812 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
10.35% less ownership
Funds ownership: 59.43% [Q2] → 49.08% (-10.35%) [Q3]
14% less funds holding
Funds holding: 37 [Q2] → 32 (-5) [Q3]
28% less capital invested
Capital invested by funds: $17M [Q2] → $12.2M (-$4.82M) [Q3]
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Research analyst outlook
We haven’t received any recent analyst ratings for BOLT.
Financial journalist opinion
Neutral
Zacks Investment Research
1 month ago
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.43 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from BDC-1001 data suggest Boltbody™ ISACs with enhanced immune activation could offer greater efficacy, warranting further testing REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today presented updated preclinical data for BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targeting claudin 18.2, and provided key learnings from its Phase 1 dose-escalation trial of BDC-1001 at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in Houston, Texas from November 6-10, 2024.
Neutral
Accesswire
3 months ago
Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
Neutral
Accesswire
3 months ago
The Schall Law Firm Invites Investors To Contribute To A Securities Fraud Lawsuit Against Bolt Biotherapeutics Inc
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
Neutral
GlobeNewsWire
3 months ago
Bolt Biotherapeutics Announces Changes to its Board of Directors
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sofinnova, will be stepping down as Lead Independent Director. In addition, Frank D. Lee will be departing the Board and Brian O'Callaghan, CEO of Deep Genomics, will be assuming the role of Chair.
Neutral
Accesswire
3 months ago
Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
Neutral
PRNewsWire
3 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT
NEW YORK , Sept. 3, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT) and certain officers.
Neutral
Accesswire
3 months ago
The Schall Law Firm Invites Investors In Bolt Biotherapeutics Inc To Participate In A Securities Fraud Lawsuit
LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
Neutral
Accesswire
3 months ago
BOLT FINAL DEADLINE: Bronstein, Gewirtz and Grossman, LLC Reminds Bolt Biotherapeutics, Inc. Shareholders of Final Hours to Lead Class Action!
NEW YORK CITY, NY / ACCESSWIRE / September 3, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt securities between February 5, 2021, and May 14, 2024, inclusive (the "Class Period").
Neutral
PRNewsWire
3 months ago
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES , Sept. 3, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ: BOLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Charts implemented using Lightweight Charts™